OasisLMS

Chronic liver diseases are responsible for substantial mortality and morbidity throughout the world, annually causing approximately two million deaths globally and, in the U.S. alone, $32.5 billion in associated healthcare costs. Biopsy, the gold standard clinical test, is not suitable for screening or for longitudinal surveillance of liver disease because it is invasive and poses significant risks to the patient. Other clinical tests typically lack specificity and are insensitive to early disease stages, when interventions would benefit patients the most.

Combining dynamic MRI and PET imaging protocols with pharmacokinetic modeling, the Molecular and Cellular Imaging Lab at Michigan State University, is interested in developing a non-invasive imaging procedure for early detection and stratification of liver diseases. These studies have thus far spanned rodents to dogs and pigs with an eye towards human translation.

This activity does not offer CE Credits.


COPYRIGHT: All faculty in this activity have given their permission for publication ©2026 AASLD.